Skip to main content
Top
Published in: BMC Gastroenterology 1/2013

Open Access 01-12-2013 | Research article

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

Published in: BMC Gastroenterology | Issue 1/2013

Login to get access

Abstract

Background

The detection of serum tumor marker becomes a common method for screening tumors. However, this method has not been widely used for routine gastric cancer screening. In this study we aimed to determine whether the combined use of tumor markers may increase the sensitivity for the diagnosis of gastric cancer.

Methods

Serum AFP, CEA, CA125 and CA19-9 levels were measured in 149 patients with gastric cancer, 111 patients with benign gastric diseases and 124 healthy people, who visited the First Affiliated Hospital of Nanchang University from May 2011 to May 2012. Statistical analysis including receiver operating characteristic (ROC) curve, the area under the curve (AUC), and logistic regression analysis was performed to evaluate the diagnostic value of these markers on gastric cancer.

Results

Serum levels of CEA, CA125, and CA19-9 in gastric cancer group were higher than that in the benign gastric disease group and the healthy control group (P <0.005). The sensitivity of AFP, CEA, CA125 and CA19-9 in the diagnosis of gastric cancer was 4.7-20.8% individually, and increased to 40.3% in combination. By using optimal cut-off value, the sensitivity of CEA, CA125, and CA19-9 for the diagnosis of gastric cancer was improved. Especially, the sensitivity of CEA increased to 58.4% and the sensitivity of combined use of four markers increased to 69.1%. The age and gender had no effects on the diagnostic value of these markers.

Conclusions

The determination and application of optimal cut-off values based on ROC curve and logistic regression analysis could improve the diagnosis of gastric cancer based on common tumor markers.
Literature
1.
go back to reference Jackson C, Cunningham D, Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 34-36.PubMed Jackson C, Cunningham D, Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 34-36.PubMed
2.
go back to reference Haglund C, Kuusela P, Roberts P, Jalanko H: Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest. 1991, 51 (3): 265-270. 10.3109/00365519109091613.CrossRefPubMed Haglund C, Kuusela P, Roberts P, Jalanko H: Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest. 1991, 51 (3): 265-270. 10.3109/00365519109091613.CrossRefPubMed
3.
go back to reference Ychou M, Duffour J, Kramar A: Clinical significance and prognostic Value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000, 16 (3–4): 105-110.CrossRefPubMedPubMedCentral Ychou M, Duffour J, Kramar A: Clinical significance and prognostic Value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000, 16 (3–4): 105-110.CrossRefPubMedPubMedCentral
4.
go back to reference Li Y, Yang Y, Lu M: Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011, 58 (112): 2166-2170.CrossRefPubMed Li Y, Yang Y, Lu M: Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011, 58 (112): 2166-2170.CrossRefPubMed
5.
go back to reference Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P: Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012, 12: 10-10.1186/1471-230X-12-10.CrossRefPubMedPubMedCentral Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P: Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012, 12: 10-10.1186/1471-230X-12-10.CrossRefPubMedPubMedCentral
6.
go back to reference Zur B, Holdenrieder S, Walgenbach-Brünagel G, Albers E, Stoffel-Wagner B: Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500. Clin Lab. 2012, 58 (1–2): 97-105.PubMed Zur B, Holdenrieder S, Walgenbach-Brünagel G, Albers E, Stoffel-Wagner B: Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500. Clin Lab. 2012, 58 (1–2): 97-105.PubMed
7.
go back to reference Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W: The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab. 2012, 58 (5–6): 419-426.PubMed Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W: The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab. 2012, 58 (5–6): 419-426.PubMed
8.
go back to reference Lai IR, Lee WJ, Huang MT: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterol. 2002, 49: 1157-1160. Lai IR, Lee WJ, Huang MT: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterol. 2002, 49: 1157-1160.
9.
go back to reference Chen XZ, Zhang WK, Kun Y: Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 2012, 39: 9031-9039. 10.1007/s11033-012-1774-x.CrossRefPubMed Chen XZ, Zhang WK, Kun Y: Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 2012, 39: 9031-9039. 10.1007/s11033-012-1774-x.CrossRefPubMed
10.
go back to reference Duraker N, Celik AN: The prognostic significance of preoperative serum CA 19–9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001, 76 (4): 266-271. 10.1002/jso.1044.CrossRefPubMed Duraker N, Celik AN: The prognostic significance of preoperative serum CA 19–9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001, 76 (4): 266-271. 10.1002/jso.1044.CrossRefPubMed
11.
go back to reference Fan B, Xiong B: Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology. 2011, 58 (105): 239-245.PubMed Fan B, Xiong B: Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology. 2011, 58 (105): 239-245.PubMed
12.
go back to reference Mihmanli M, Dilege E, Demir U: The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004, 51 (59): 1544-1547.PubMed Mihmanli M, Dilege E, Demir U: The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004, 51 (59): 1544-1547.PubMed
13.
go back to reference Wobbes T, Thomas CM, Segers MF: Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992, 69 (8): 2036-2041. 10.1002/1097-0142(19920415)69:8<2036::AID-CNCR2820690805>3.0.CO;2-M.CrossRefPubMed Wobbes T, Thomas CM, Segers MF: Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992, 69 (8): 2036-2041. 10.1002/1097-0142(19920415)69:8<2036::AID-CNCR2820690805>3.0.CO;2-M.CrossRefPubMed
Metadata
Title
Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer
Publication date
01-12-2013
Published in
BMC Gastroenterology / Issue 1/2013
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-13-87

Other articles of this Issue 1/2013

BMC Gastroenterology 1/2013 Go to the issue